Home › Non-Small Cell Lung Cancer › Maine
Non-Small Cell Lung Cancer clinical trials in Maine
16 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Maine.
Cities in Maine
- West Scarborough7 studies
- South Portland7 studies
- Bangor5 studies
- Sanford4 studies
- South Portland Gardens4 studies
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- Lafayette Family Cancer Center-EMMC, Brewer
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- MaineHealth Coastal Cancer Treatment Center, Bath
- MaineHealth Cancer Care and IV Therapy - Brunswick, Brunswick
- MaineHealth Maine Medical Center - Portland, Portland
- and 3 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07293247A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- New England Cancer Specialists ( Site 0139), Westbrook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07190248Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Maine Medical Center- Scarborough, Scarborough
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06498635A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- New England Cancer Specialists ( Site 0095), Westbrook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312137This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Maine Medical Center, Portland
- MaineHealth Cancer Care and Blood Disorders Scarborough, Scarborough
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- New England Cancer Specialists ( Site 0143), Westbrook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06170788Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- New England Cancer Specialists, Westbrook
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06890598A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Scarborough
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06692738Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, South Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07291037Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Lafayette Family Cancer Center-EMMC, Brewer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Lafayette Family Cancer Center-EMMC, Brewer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Lafayette Family Cancer Center-EMMC, Brewer
RecruitingPhase 2
18 Minutes · All sexes · Updated May 5, 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- Lafayette Family Cancer Center-EMMC, Brewer
- and 5 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT06616584Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- MaineHealth Maine Medical Center - Biddeford, Biddeford
- and 7 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 17, 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scarborough
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.